Simbec-Orion, a mid-sized Contract Research Organization, and biotx.ai, a company specializing in AI-powered causal modeling for drug development, have officially revealed their strategic partnership

ReHeva Biosciences, an innovative biopharmaceutical startup, is thrilled to announce the successful completion of its Phase I Safety Trial for its groundbreaking drug, RH324. This achievement represents a major milestone in the company's

Turbine, a computational biology company specializing in empirically validated in silico cell simulations for guiding biopharmaceutical research and development, has announced a collaborative partnership

Elektrofi, Inc., a biopharmaceutical formulation technology company specializing in strategic partnerships to revolutionize the delivery of biologic therapies, has announced a multi-target research collaboration and license agreement with Eli Lilly

Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored immunotherapies for cancer treatment, has received approval for its investigational new drug application from the U.S. Food & Drug Administration

Kiromic BioPharma, Inc. has made a significant announcement regarding its clinical initiatives. The company, a pioneer in the field of biotherapeutics, is utilizing its exclusive DIAMOND® artificial intelligence

Iksuda Therapeutics, a company specializing in the development of innovative antibody drug conjugates with enhanced tumor specificity, has announced a significant milestone in its clinical trials. The first patient has successfully completed the initial treatment cycle of IKS014, an antibody-drug

Amgen, a company listed on NASDAQ under the symbol AMGN, has unveiled the findings from the global Phase 2 DeLLphi-301 study. This study assessed the efficacy of tarlatamab

Rise Therapeutics, a biotechnology company specializing in the development of novel oral immunotherapeutics, has announced that the U.S. Food and Drug Administration has approved its investigational new drug

Qnovia, Inc., a pharmaceutical company specializing in the development of inhaled therapeutic products across various medical fields, has announced a collaborative effort with the University of Virginia to advance innovative inhaled drug candidates